Keybank National Association OH Sells 327,696 Shares of Lantheus Holdings, Inc. $LNTH

Keybank National Association OH cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 63.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,026 shares of the medical equipment provider’s stock after selling 327,696 shares during the quarter. Keybank National Association OH owned 0.28% of Lantheus worth $9,593,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its holdings in Lantheus by 77.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,159 shares of the medical equipment provider’s stock valued at $495,000 after buying an additional 2,695 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Lantheus by 17.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 31,388 shares of the medical equipment provider’s stock valued at $2,569,000 after acquiring an additional 4,677 shares during the period. Truist Financial Corp increased its position in Lantheus by 6.1% in the 2nd quarter. Truist Financial Corp now owns 6,696 shares of the medical equipment provider’s stock valued at $548,000 after acquiring an additional 382 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Lantheus by 25.4% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 4,984 shares of the medical equipment provider’s stock valued at $408,000 after acquiring an additional 1,009 shares during the last quarter. Finally, Hardy Reed LLC lifted its holdings in shares of Lantheus by 97.3% during the second quarter. Hardy Reed LLC now owns 23,000 shares of the medical equipment provider’s stock worth $1,882,000 after purchasing an additional 11,340 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

NASDAQ:LNTH opened at $66.92 on Monday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a fifty day moving average of $64.87 and a 200-day moving average of $59.77. The firm has a market capitalization of $4.44 billion, a P/E ratio of 28.12 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million for the quarter, compared to analyst estimates of $363.42 million. During the same period in the prior year, the firm earned $1.70 earnings per share. Lantheus’s revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on LNTH shares. Mizuho increased their price objective on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial increased their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.